Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s MHLW And Baxter In Talks To Bring New Flu Vaccines To Japan

This article was originally published in PharmAsia News

Executive Summary

U.S. major drug maker Baxter International June 16 disclosed that the company is talking with Japan's Ministry of Health, Labor and Welfare about exporting new H1N1 flu vaccines to Japan. Baxter said a negotiation toward signing a supply contract with the MHLW is ongoing and the first shipment could be ready as early as July. Currently, four Japanese domestic vaccine makers including Kitazato Institute are preparing to manufacture flu vaccines for the new H1N1 flu virus; however, due to limited production capability, the MHLW has been actively looking for additional supplies from overseas vaccine makers. Using cell engineering technology rather than the conventional egg method, Baxter is capable of producing a large amount of H1N1 vaccine in a shorter period of time. Baxter plans a July shipment, and could supply the world's first H1N1 vaccines ahead of Novartis. (Click here for more - Japanese Language

You may also be interested in...



Podcast: Living In China's Coronavirus Lockdown, Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches

Scrip's Brian Yang describes what life is like in China as the authorities battle to contain the coronavirus, and drug developers race to find vaccine and anti-virals against the new threat. Plus news on Novartis' bold initiative with England on inclisiran, and what lies ahead for Biogen and Alzheimer's treatment in 2020

Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology

Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.

China Uses Old To Fight New As Repurposed Drugs Take Coronavirus Role

Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.

UsernamePublicRestriction

Register

SC071925

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel